Efranat Pharma is developing an anticancer immunotherapy treatment based on a natural plasma protein molecule. The technology is based on the concept of engaging the bodys own immune system and harnessing it against cancer.

Efranat has succeeded in engineering a natural vitamin D binding protein into a potent immune modulator to fight cancer and chronic viral diseases. The companys primary product, EF-022, is an immunomodulator that activates macrophages, a group of white blood cells that play a key role in the immune systems defense against cancer. The product is manufactured and processed under GMP in a procedure that mimics the natural process in the body.

A test involving 14 dogs with cancer that were treated with EF-022 showed promising results. Efranat is currently conducting a phase 1 clinical trial in human cancer patients with advanced solid tumors at the Sheba Medical Center.